Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiological response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kYcnQv
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vzMRTg via IFTTT
-
Vol.83 No.3 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TkQfWM via IFTTT
-
Editorial introductions No abstract available Editorial: COVID-19 in older persons: the role of nutrition No abstract available A year with ...
-
Small size of metastatic lymph nodes with extracapsular spread greatly impacts treatment outcomes in oral squamous cell carcinoma patie...
-
Abstract We generated an alternative reverse genetics (RG) system based on a synthesized swine 45S rRNA promoter to rescue the H3N2 subtype...
-
Abstract In present work, the electronic structure and optical properties of the FeX 2 (X = S, Se, Te) compounds have been evaluated by t...
-
A frame deformation estimation algorithm is investigated for the purpose of real-time control and health monitoring of flexible lightweight ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου